Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge

Phase

N/A

Condition

Diabetic Neuropathy

Diabetic Gastroparesis

Diabetic Foot Ulcers

Treatment

Continuous Glucose Monitor

Blood Glucose Monitor

Clinical Study ID

NCT05548205

22-01051

Ages 18-100
All Genders

Study Summary

The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for 2 weeks or blood glucose monitoring (BGM) for 2 weeks. They will have a 2-week follow up visit, during which insulin doses will be adjusted as needed, and a 3-month follow-up visit, at which point HbA1c will be measured.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Male or female aged 18-100 years
Known history of type 1 or type 2 diabetes
Admitted to NYU Langone Hospital - Long Island between December 16, 2024- December 31, 2026
New initiation of insulin therapy, including basal insulin regimen, basal-bolusinsulin regimen, or mixed insulin regimen at the time of hospital discharge

Exclusion

Exclusion Criteria:

Prior to admission use of home insulin therapy
Current use of systemic corticosteroids
Active pregnancy; as pregnancy requires different blood glucose targets, subjectsknown to be pregnant will be excluded from this study. Subjects will not be testedfor pregnancy outside of testing performed in routine medical care; pregnancy willbe determined by patient self-reporting. Females of childbearing potential will notbe instructed to avoid pregnancy, however if they became pregnant during the study (detected by self-reporting), they will be withdrawn from the study.

Study Design